Trial Profile
Multicenter Double-blinded Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy, Safety and Choice of an Optimum Dose of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections in Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2019
Price :
$35
*
At a glance
- Drugs XC-221 (Primary)
- Indications Influenza virus infections; Respiratory tract infections; Viral infections
- Focus Therapeutic Use
- Sponsors Pharmenterprises
- 14 Oct 2019 Status changed from recruiting to completed.
- 13 Mar 2018 New trial record